Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Oct;64(10):1822-1829.
doi: 10.1111/trf.17995. Epub 2024 Oct 3.

How do we manage hyperhemolysis syndrome

Brian D Adkins  1   2 , Samer Z Kaylani  2   3 , Alecia Nero  2   3   4 , Ibrahim F Ibrahim  4 , Yu-Min Shen  4 , Ravindra Sarode  1
Affiliations

How do we manage hyperhemolysis syndrome

Brian D Adkins et al. Transfusion. 2024 Oct.

Abstract

Background: Hyperhemolysis syndrome (HHS) is a catastrophic anemia characterized by destruction of both donor and patient red blood cells (RBC). HHS occurs after transfusion and can cause significant morbidity and mortality. Given the difficulty in diagnosing and managing this process, we provide a detailed overview of our treatment protocol.

Study design and methods: Members of the Transfusion Medicine and Hematology faculty at our institution collaborated in an iterative process to produce a consensus approach to patients with HHS.

Results: We present diagnostic criteria for HHS: recent transfusion within past 7 days (up to 21 days), rapid hemoglobin decline to below the pretransfusion level (usually hemoglobin drop >25% from pretransfusion), a significant decrease in HbA% (in patients with sickle cell disease or beta thalassemia), low or decreasing reticulocyte count in a patient with worsening anemia, and laboratory evidence of hemolysis. We also describe an in-depth approach to management focusing on optimizing hematopoiesis while dampening the immune response.

Conclusion: We provide a comprehensive approach to the diagnosis and management of HHS based on contemporary literature and clinical experience designed to optimize outcomes for patients.

Keywords: RBC transfusion; hematology – red cells; transfusion complications‐non infectious.

PubMed Disclaimer

References

REFERENCES

    1. Jacobs JW, Stephens LD, Allen ES, Binns TC, Booth GS, Hendrickson JE, et al. Epidemiological and clinical features, therapeutic strategies and outcomes in patients with hyperhaemolysis: a systematic review. Br J Haematol. 2023;201:1025–1032.
    1. Petz LD. Bystander immune cytolysis. Transfus Med Rev. 2006;20:110–140.
    1. Petz LD, Garratty G. Drug‐induced immune hemolytic anemia. Immune hemolytic anemias. 2nd ed. Philadelphia, PA: Churchill Livingstone; 2004.
    1. Cid J, Fernández J, Palomo M, Blasco M, Bailó N, Diaz‐Ricart M, et al. Hyperhemolytic transfusion reaction in non‐hemoglobinopathy patients and terminal complement pathway activation: case series and review of the literature. Transfus Med Rev. 2020;34:172–177.
    1. Merle NS, Grunenwald A, Rajaratnam H, Gnemmi V, Frimat M, Figueres ML, et al. Intravascular hemolysis activates complement via cell‐free heme and heme‐loaded microvesicles. JCI Insight. 2018;3:3.

LinkOut - more resources